佩波瑟蒂布抑制了由反侧双尼克形成的FLT3内部合重复的产生
Shota Yoshida1, Masahiro Onozawa1, Shota Yokoyama1
1Department of Hematology, Hokkaido University Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan.
Experimental hematology
|June 2, 2025
概括
在急性骨髓性白血病中,Fms类氨酸激酶3-内部协同重复 (FLT3-ITD) 突变是由特定不稳定的区域的DNA损伤引起的. DNA双链断裂修复,而不是单链断裂修复,对于FLT3-ITD生成至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 类似FMS的氨酸激酶3-内部协同重复 (FLT3-ITD) 是急性髓性白血病的一个常见突变.
- 产生FLT3-ITD突变的精确分子机制尚未完全理解.
研究的目的:
- 阐明FLT3-ITD产生背后的分子机制.
- 研究DNA修复途径在FLT3-ITD形成中的作用.
主要方法:
- 临床样本的深度测序以确定FLT3-ITD特征.
- 在细胞系中进行CRISPR/Cas9基因编辑以诱导人工FLT3-ITDs.
- 对ITD形成的DNA修复抑制剂 (olaparib和peposertib) 的检测.
主要成果:
- 在FLT3的第14个外显子中,存在一种类似于帕林德罗姆的序列,容易导致遗传不稳定性和DNA损伤.
- 由CRISPR/Cas9生成的人工FLT3-ITD模仿了临床ITD.
- 抑制DNA双链断裂修复 (使用peposertib) 显著降低了ITD的形成,而抑制单链断裂修复 (olaparib) 没有影响.
结论:
- 在FLT3外显子14的基因组不稳定性,由其类似于Palindrome的序列驱动,启动FLT3-ITD的形成.
- 非同类末端连接,DNA双链断裂修复途径,在产生FLT3-ITD中发挥着关键作用.
- 佩索塞蒂布可以通过干扰DNA损伤错误修复事件来抑制新的FLT3-ITD生成.
相关概念视频
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:02Long-patch Base Excision Repair
7.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.2K